New combo aims to keep stomach cancer at bay longer
NCT ID NCT04021108
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding radiation therapy to the immunotherapy drug nivolumab can help people with advanced gastroesophageal cancer live longer without their disease getting worse. All 80 participants first receive a short course of chemotherapy (FOLFOX) plus nivolumab. Those whose cancer does not grow are then randomly assigned to continue nivolumab alone or nivolumab plus radiation. The main goal is to see how many patients are still progression-free after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo) and radiation therapy
What this could lead to
If successful, this could point toward a more effective treatment strategy for advanced gastroesophageal cancer, potentially extending the time patients live without their cancer growing.
What could go wrong
This is a small, early-phase study (80 people) and results may not apply to all patients. Adding radiation to immunotherapy also carries risks of increased side effects, and the benefit over standard care is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Center
Buffalo, New York, 14203, United States
-
University of Nebraska
Omaha, Nebraska, 68105, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States